海角社区app appoints Michael Shih as Chief Executive Officer
鈥� Highly experienced corporate development leader with a track record of international pharma and biotech deal-making
鈥� New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer
London UK, 16 December 2024 鈥� 海角社区app Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive Officer (CEO) and to the Board of Directors, effective immediately.
Michael Shih has nearly 20 years of experience in business development, licensing and mergers & acquisitions. Michael was most recently Vice President of Corporate Development at Kite Pharma, where he led multiple business development opportunities for the Company. Before this, Michael was Senior Vice President, Head of Business Development at Biogen, leading the team responsible for sourcing, structuring and executing strategic collaborations and merger and acquisition opportunities. Prior to joining Biogen, Michael was Vice President and Head of Global Transactions at Sanofi, where he oversaw the structuring and negotiation of business development transactions across Sanofi鈥檚 business units. Michael has also held senior business development roles at Epizyme, Forest Laboratories and Eisai.
Robert James, Chairman of the Board, 海角社区app, said: 鈥淢ichael joins at an exciting stage in 海角社区app鈥檚 development having raised a significant Series B financing round which was supported by Bristol Myers Squibb. As we move closer to being a clinical Company Michael鈥檚 experience as a corporate development leader in pharma and biotech will be instrumental in driving 海角社区app鈥檚 next phase of growth.鈥�
Michael Shih, newly appointed Chief Executive Officer and Board of Director, 海角社区app commented: 鈥満＝巧缜鴄pp鈥檚 differentiated approach to targeting the MMR pathway has huge potential to treat cancer. I am looking forward to working with the highly experienced 海角社区app team, who are all clearly aligned to advance the Company鈥檚 pipeline.鈥�
An attorney by training, Mr. Shih previously practiced law at several New York firms and held senior legal positions in-house at Eisai Inc., specialising in licensing, corporate transactions, and litigation.
海角社区app is developing a pipeline of highly validated, first-in-class small molecule drugs targeting proteins across the MMR pathway to improve the efficacy and durability of revolutionary immunotherapies to treat cancer. The appointment of Michael Shih as CEO follows the close of the Company鈥檚 oversubscribed Series B financing. The financing and new appointment of the CEO strengthen 海角社区app's position to drive its growth strategy and maximise the potential of its pipeline.
鈥� Ends 鈥�
For more information, please contact:
Optimum Strategic Communications
Hana Malik, Aoife Minihan
Tel: +44 20 3922 0891
neophore@optimumcomms.com
NOTES TO EDITORS
About 海角社区app Ltd
海角社区app, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients鈥� immune system to overcome natural defence mechanisms in cancer. The Company鈥檚 approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, 海角社区app aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. 海角社区app was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit www.neophore.com